Etanercept biosimilar - Coherus Biosciences/Daiichi Sankyo

Drug Profile

Etanercept biosimilar - Coherus Biosciences/Daiichi Sankyo

Alternative Names: BAX 2200; CHS-0214

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences; Daiichi Sankyo Company
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 05 Jul 2017 Discontinued - Phase-III for Plaque psoriasis in Japan (SC)
  • 05 Jul 2017 Discontinued - Phase-III for Rheumatoid arthritis (Treatment-experienced) in Japan (SC)
  • 14 Jun 2017 Safety and efficacy data from an open-label extension phase III trial in Rheumatoid arthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top